TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05177666
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.
Study: NCT06310876
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: • single oral dose
Study: NCT04794530
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo intervention will be manufactured by Mars Inc. and will appear identical to the cocoa flavanols intervention. Participants will take two capsules daily of placebo. The placebo will be a cellulose based capsule and will not contain cocoa flavanols or (-)-epicatechin.
Study: NCT04596267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert ingredients
Study: NCT04895423
Drug: Methotrexate therapy
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate subcutaneously 10-15 mg/m2 once every 7 days within 12 months
Study: NCT04895423
Drug: Mycophenolate mofetil therapy
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil per os 500-700 mg/m2 2 times a day within 12 months
Study: NCT05926804
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days of Clarithromycin (500 mg BID) (days 8-14)
Study: NCT05277766
Drug: PIPAC with Nal-IRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanoliposomal irinotecan (Nal-IRI, Onivyde) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 30 to 90 mg/m². PIPAC will be performed every 4 to 6 weeks for 3 cycles.
Study: NCT05356897
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05670470
Drug: CTP0303
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized into group CTP0303 will receive bowel preparation from evening to next morning.
Study: NCT05670470
Drug: Orafang Tab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized into group Orafang Tab will receive bowel preparation from evening to next morning.
Study: NCT05772039
Drug: Topical application of 5% Sodium Fluoride with functional Tricalcium phosphate Varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: * According to manufacturer, Clinpro® White Varnish can be applied to tooth surfaces where plaque is present. A prophylaxis is not required.~* The applicator brush provided along is used to thoroughly mix the varnish inside the single-unit dose pack, since components of all sodium fluoride varnishes are separate during storage.~* Excessive contact with soft tissue should be avoided.~* Only enough varnish to form a thin coating on the desired treatment area should be used.~* After application, patient should be instructed to close their mouth to set the varnish.~* Rinsing or suctioning immediately after application is not recommended.~* The operator might appreciate the formation of a thin coating on the teeth and the patient should be informed that they may feel a thin coating when rubbing the treated area with their tongue.
Study: NCT06481306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT04232358
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections are administered ultrasound guided in the bursa adjacent to the achilles tendon insertion every 4 weeks until symptoms resolve with at maximum of 3 injections.
Study: NCT05762276
Drug: VXX-401
Approvals — FDA: no, EMA: no, PMDA: no
Description: A synthetic PCSK9 peptide-based immunotherapy
Study: NCT05163522
Drug: VH4004280
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4004280 will be administered.
Study: NCT05163522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT00455039
Drug: GW572016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 1500 mg daily
Study: NCT06060626
Drug: Sedation using combination of Propofol and Fentanyl.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in whom combination of propofol and fentanyl will be administered during sedation.
Study: NCT04137640
Drug: epirubicin combined with cyclophosphamide and sequential docetaxel
Normalized name: picodralazine and diuretics, combinations with psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy group will receive epirubicin combined with cyclophosphamide and sequential docetaxel: epirubicin (Pfizer Wuxi Pharmaceutical Plant, Wuxi, China; license number: GYZZ H20000496), 90 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times; cyclophosphamide (Baxter Oncology GmbH, Halle, Germany; license number: H20160468), 600 mg/m2, once every four weeks, totally four times; sequential docetaxel (Sanofi-aventis Deutschland GmbH, Frankfurt am Main, Germany; license number: GYZZ J20150083) 75 mg/m2, intravenously, for 120 minutes, once every four weeks, totally four times.
Study: NCT05698550
Drug: Erzhi Tiangui Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Drug Manufacturing Unit of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine produced the EZTG granule.The EZTG was packaged as 3 g/bag, batch number 01-FZ032-03. The daily dose is equivalent to 15g of Ligustrum lucidum (Nv Zhen Zi),15g of Lotus japonicus (Han Lian Cao),15g of the fruit of Chinese wolfberry(Gou Qi Zi),15g of Cuscuta chinensis(Tu Si Zi), 15g of Radix Rehmanniae Preparata(Shu Di Huang),12g of Angelica sinensis(Dang Gui),12g of Paeonia lactiflora(Bai Shao),12g of Ligusticum wallichii(Chuan Xiong),12g of Rhizoma cyperi(Xiang Fu),and 9g of Radix Glycyrrhizae (Zhi Gan Cao).The placebo granule,which was Preparata mainly composed of dextrin, was made in a similar color and shape to EZTG.Placebo granules were packaged as 3g/bag, with the same package of the EZTG, batch number 01-FZ032-03-1. The EZTG or placebo was orally administered after being dissolved in water, 3g each time, 2 times a day.
Study: NCT05698550
Drug: Erzhi Tiangui Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo consisted mainly of yellow bean powder, starch, carbogen, molasses and could mimic the appearance, color and smell of Erzhi Tiangui granules, but without any active ingredients. Daily doses of placebo were delivered in the same packaging as Erzhi Tiangui granules.
Study: NCT06209268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl 1 ml per day in five consecutive days
Study: NCT05778617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT06122831
Drug: TQ05105 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor.
Study: NCT06122831
Drug: TQB3617 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3617 Capsules is a Bromodomain and Extra-Terminal (BET) Inhibitor
Study: NCT05376150
Drug: XEN1101 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN1101 oral capsule
Study: NCT05376150
Drug: XEN1101 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN1101 oral capsule
Study: NCT05376150
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT05697328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
Study: NCT05122975
Drug: S48168 (ARM210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ryanodine Receptor modulator
Study: NCT05122975
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of same size and consistency as S48168 (ARM210)
Study: NCT05136326
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/sqm/bid per os (p.o.) 5 days/week for 5 weeks;
Study: NCT05076006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT05455060
Drug: Chinese herbal formula (CHF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each CHF capsule, weighing 500mg, is composed of Xiao-Feng-San 200mg, Zhen-Ren-Huo-Ming-Yin 200mg, Dictamnus dasycarpus 50mg and Houttuynia cordata 50mg. Patients will take the medicine 2 times a day (6gm BID for BW≥40kg), for 12 weeks, and the dosage will be modified according to patients' body weight. (3gm BID for 20kg≦BW\<40kg; 1.5gm BID for BW\<20kg)
Study: NCT05455060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients in control group will take the placebo capsules, which has the similar look, smell, and taste. The dosage, frequency, and duration are the same as CHF group.
Study: NCT05614817
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous(SC) injection
Study: NCT06553937
Drug: PrOpsynvi® Film-Coated Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Study: NCT06116045
Drug: Placebo (1.5 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZ371A-matched placebo
Study: NCT06116045
Drug: Placebo (1.0 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZ371A-matched placebo
Study: NCT06116045
Drug: Placebo (0.5 ml)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZ371A-matched placebo
Study: NCT04735471
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for Lymphodepletion
Study: NCT01796795
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
Study: NCT01796795
Drug: SR-T100 gel with 1.0% of SM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
Study: NCT06204003
Drug: Cannabis/Hemp Isolate Extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation: CBD (99%; 0.1% THC isolate)
Study: NCT06428331
Drug: SKB518 for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKB518 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
Study: NCT06076837
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)
Study: NCT05530252
Drug: Oral biological antimicrobial gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were divided into subgingival scaling, and Oral Biological Antimicrobial Gel was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
Study: NCT05530252
Drug: minocycline hydrochloride ointment
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients were divided into subgingival scaling, and minocycline hydrochloride ointment was used in the periodontal pocket after scaling. The injection probe with gel was inserted into the periodontal pocket, and the injection was slowly pushed, and the injection was gradually withdrawn during the injection, until a little gel was found at the mouth of the bag.
Study: NCT05913232
Drug: H-1337 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution
Study: NCT05913232
Drug: H-1337 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution
Study: NCT05913232
Drug: H-1337 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution
Study: NCT05891379
Drug: oral immunosuppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunosuppressants (azathioprine or mycolate mofetil) are initiated during IVMP.
Study: NCT06519578
Drug: hepatic artery infusion chemotherapy
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAIC is a regional therapy that takes advantage of the fact that hepatic tumors, particularly hepatocellular carcinoma, predominantly receive their blood supply from the hepatic artery. The procedure typically involves the insertion of a catheter into the hepatic artery, often through a percutaneous approach or during a surgical procedure.~FOLFOX (5-fluorouracil, leucovorin combined with oxaliplatin) or RALOX (raltitrexed combined with oxaliplatin) Q3W.
Study: NCT05278962
Drug: SGLT2i
Approvals — FDA: no, EMA: no, PMDA: no
Description: empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
Study: NCT06152991
Drug: GODEX
Normalized name: Dodex
Approvals — FDA: no, EMA: no, PMDA: no
Description: The amount of active ingredient per dose (1 capsule)~* Carnitine Orotate 150mg~* liver extract antitoxic fraction 12.5㎎~* Adenine Hydrochloride 2.5mg~* Pyridoxine Hydrochloride 25mg~* Riboflavin 0.5mg~* Cyanocobalamin 0.125mg~* Biphenyl Dimethyl Dicarboxylate 25mg
Study: NCT06152991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Anhydrous lactose 50mg.~* Colloidal silicon dioxide 12mg.~* Amorphous cellulose 50mg.~* Lactose monohydrate 215.625mg.~* Magnesium stearate 7mg.~* Upper and lower brown opaque capsules 77mg.
Study: NCT05655299
Drug: VTX958 Dose A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose A
Study: NCT05655299
Drug: VTX958 Dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose B
Study: NCT05655299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04708366
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Study: NCT04708366
Drug: Macrogol 400
Normalized name: Macrogol 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Study: NCT04446039
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for depression
Study: NCT04446039
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for depression
Study: NCT06651541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation without the active ingredient
Study: NCT05760781
Drug: STSG-0002 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT04762589
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 20 weeks.
Study: NCT05659953
Drug: LMT503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one of several different oral doses of LMT503 once daily
Study: NCT05659953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one of several different oral doses of Placebo once daily
Study: NCT05718921
Drug: YR001 Dose B on low body surface area
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single topical dose
Study: NCT05718921
Drug: Placebo on low body surface area
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single topical dose
Study: NCT05718921
Drug: YR001 Dose B on high body surface area twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Multiple topical dose
Study: NCT05718921
Drug: Placebo on high body surface area twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Multiple topical dose
Study: NCT02039869
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid suppressing medication (over the counter)
Study: NCT05919186
Drug: EmbryORP®
Approvals — FDA: no, EMA: no, PMDA: no
Description: EmbryORP® is a novel antioxidant (Cystein 32.9 mM, Glutation 32.6 mM, Ascorbic Acid 22.7 mM)
Study: NCT04204967
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the active comparator arm remifentanil infusion is administered alone, the infusion rate will be increased or decreased according to the study protocol based on PaCO2 value resulting from the Arterial Blood Gases sample (ABG) collected at each visit.~In the experimental arm remifentanil is use together with transdermal fentanyl
Study: NCT05886374
Drug: HMPL-415S1
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMPL-415S1 will be supplied as 0.5 mg, 5 mg and 25 mg capsules
Study: NCT00000996
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04291469
Drug: Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The probiotic compound will consist of tables containing approximately 10\^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).
Study: NCT05691530
Drug: rDENdelta30/31-7164
Approvals — FDA: no, EMA: no, PMDA: no
Description: The rDEN3delta30/31-7164 vaccine is a live attenuated virus constructed by creating two deletions in the 3 UTR of the DENV3 Sleman/78 strain. The rDEN3delta30/31-7164 vaccine will be delivered subcutaneously into the left deltoid area on day 0. The vaccine dose will consist of 0.5 mL of 10\^3 PFU/mL of rDEN3delta30/31-7164 plus Plasma-Lyte A pH 7.4 diluent.
Study: NCT05999357
Drug: JDQ443
Approvals — FDA: no, EMA: no, PMDA: no
Description: JDQ443 tablets, orally administered
Study: NCT06284265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet for oral use.
Study: NCT05169229
Drug: Vancomycin + Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 g vancomycin (powder) diluted in 8 ml tobramycin (80mg/ml). Added to the prepared allograft before the allograft is used during the revision surgery.
Study: NCT05930210
Drug: ENERGI-F703 GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care and ENERGI-F703 GEL are applied for the treatment of diabetic foot ulcers.
Study: NCT05930210
Drug: ENERGI-F703 matched vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
Study: NCT05323812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily dose of 100 mg TW001/placebo
Study: NCT06363461
Drug: TDM-180935 topical ointment 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned drug will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
Study: NCT06363461
Drug: TDM-180935 topical ointment 2.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned drug will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
Study: NCT06363461
Drug: TDM-180935 topical vehicle ointment 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients in the randomized portion of the study will be randomized (2:2:1:1) to 1 of the 4 groups. The assigned placebo will be applied once daily for 8 weeks, with application to the active lesions excluding head/neck, hands/feet, genitalia, and intertriginous areas.
Study: NCT06065670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched sugar tablet
Study: NCT03708900
Drug: LCI699
Approvals — FDA: no, EMA: no, PMDA: no
Description: osilodrostat (LCI699) is in the form of tablets for oral administration and comes in the following tablet strengths: 1 milligram (mg), 5 mg, and 10mg.
Study: NCT06654921
Drug: Standard medication therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication therapy will be performed according to the national and international guidelines.
Study: NCT04809142
Drug: TQB2450 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.
Study: NCT04809142
Drug: Capecitabine tablets
Normalized name: Capecitabine Tablets
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine tablets total dose 2000 mg/m2, oral twice a day from Day 1-14 of each 3- week cycles;
Study: NCT05119751
Drug: tree 12 SQ-Bet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAILY DOSE OF AIT TABLET
Study: NCT05119751
Drug: GRASS 2800 BAU
Normalized name: Timothy grass pollen extract 2800 BAU [Grastek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAILY DOSE OF AIT TABLET
Study: NCT05119751
Drug: HDM 12 SQ-HDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAILY DOSE OF AIT TABLET
Study: NCT05902260
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab monotherapy with or without combination chemotherapy according to standard of care
Study: NCT06601803
Drug: sterile saline solution
Normalized name: Blairex Sterile Saline Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The shoulder will be washed with normal sterile saline before and after placing the shoulder implant
Study: NCT06601803
Drug: Surgiphor
Approvals — FDA: no, EMA: no, PMDA: no
Description: The shoulder will be washed with Surgiphor (Povidone Iodine) before and after placing the shoulder implant